168 related articles for article (PubMed ID: 23180020)
21. Genotypes and haplotypes in the insulin-like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density.
Biong M; Gram IT; Brill I; Johansen F; Solvang HK; Alnaes GI; Fagerheim T; Bremnes Y; Chanock SJ; Burdett L; Yeager M; Ursin G; Kristensen VN
BMC Med Genomics; 2010 Mar; 3():9. PubMed ID: 20302654
[TBL] [Abstract][Full Text] [Related]
22. Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy.
Chang CF; Pao JB; Yu CC; Huang CY; Huang SP; Yang YP; Huang CN; Chang TY; You BJ; Lee HZ; Hour TC; Bao BY
Ann Surg Oncol; 2013 Jul; 20(7):2446-52. PubMed ID: 23397154
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
24. IGF gene polymorphisms and breast cancer in African-American and Hispanic women.
Sarkissyan M; Mishra DK; Wu Y; Shang X; Sarkissyan S; Vadgama JV
Int J Oncol; 2011 Jun; 38(6):1663-73. PubMed ID: 21455574
[TBL] [Abstract][Full Text] [Related]
25. Association between HER2 and IL-6 genes polymorphisms and clinicopathological characteristics of breast cancer: significant role of genetic variability in specific breast cancer subtype.
Bouhniz OE; Zaied S; Naija L; Bettaieb I; Rahal K; Driss M; Kenani A
Clin Exp Med; 2020 Aug; 20(3):427-436. PubMed ID: 32372374
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
27. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.
Snoussi K; Mahfoudh W; Bouaouina N; Fekih M; Khairi H; Helal AN; Chouchane L
BMC Cancer; 2010 Jun; 10():283. PubMed ID: 20540789
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Charehbili A; van Laarhoven HW; Mooyaart AL; Dekker-Ensink NG; van de Ven S; Janssen LG; Swen JJ; Smit VT; Heijns JB; Kessels LW; van der Straaten T; Böhringer S; Gelderblom H; van der Hoeven JJ; Guchelaar HJ; Pijl H; Kroep JR;
Breast Cancer Res; 2016 Jan; 18(1):3. PubMed ID: 26738606
[TBL] [Abstract][Full Text] [Related]
29. Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density.
Verheus M; McKay JD; Kaaks R; Canzian F; Biessy C; Johansson M; Grobbee DE; Peeters PH; van Gils CH
Breast Cancer Res Treat; 2008 Nov; 112(1):109-22. PubMed ID: 18064566
[TBL] [Abstract][Full Text] [Related]
30. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
31. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
32. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Coté D; Eustace A; Toomey S; Cremona M; Milewska M; Furney S; Carr A; Fay J; Kay E; Kennedy S; Crown J; Hennessy B; Madden S
PLoS One; 2018; 13(8):e0200996. PubMed ID: 30071039
[TBL] [Abstract][Full Text] [Related]
33. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
34. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
[TBL] [Abstract][Full Text] [Related]
35. Single nucleotide polymorphisms of insulin-like growth factor gene and mammographic breast density.
Smolarz B; Wójcik L; Romanowicz H
Prz Menopauzalny; 2020 Dec; 19(4):160-170. PubMed ID: 33488326
[TBL] [Abstract][Full Text] [Related]
36. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
37. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
Cresti N; Lee J; Rourke E; Televantou D; Jamieson D; Verrill M; Boddy AV
Eur J Cancer; 2016 Mar; 55():27-37. PubMed ID: 26773371
[TBL] [Abstract][Full Text] [Related]
38. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor 1 gene polymorphism in women with breast cancer.
Costa-Silva DR; da Conceição Barros-Oliveira M; Borges RS; Campos-Verdes LM; da Silva-Sampaio JP; Escorcio-Dourado CS; Martins LM; Alencar AP; Baracat EC; Silva VC; da Silva BB
Med Oncol; 2017 Apr; 34(4):59. PubMed ID: 28315227
[TBL] [Abstract][Full Text] [Related]
40. Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes.
Huang AJ; Yu KD; Li J; Fan L; Shao ZM
PLoS One; 2012; 7(5):e35252. PubMed ID: 22586447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
